翰森制药圣罗莱首个治疗EPO诱导的PRCA病例报道在NKF官方期刊发表

Core Insights - The study published in the journal "Kidney Medicine" demonstrates the effectiveness of the peptide, Pemolizumab, in treating EPO-induced Pure Red Cell Aplasia (PRCA) patients, indicating a promising innovative solution for this rare but serious complication [1] Group 1: Research Findings - The research led by Professor Fan Qiuling from Shanghai Jiao Tong University School of Medicine shows that Pemolizumab can effectively treat EPO-induced PRCA in a non-dialysis Chinese patient with type 1 diabetes nephropathy [1] - The study confirmed Pemolizumab's potential in treating EPO-induced PRCA, as evidenced by significant improvements in hemoglobin levels and anemia symptoms without notable adverse reactions [1] Group 2: Clinical Implications - The findings provide a new safe, effective, and convenient treatment option for EPO-induced PRCA, addressing a critical need in clinical practice [1] - The patient's clinical course, reticulocyte count reduction, and bone marrow biopsy results were consistent with EPO treatment-induced PRCA, reinforcing the study's conclusions [1]